Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36063832

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Haematol
Publication date
2022 Oct
First author
Bazinet A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2022 Oct;9(10):e714-e716. doi: 10.1016/S2352-3026(22)00252-6.
    note
    Source null
    related pmid
    36063831
    relationship
    Comment in

Authors and identifiers

  1. name
    Bazinet A
    type
    Author
  2. name
    Darbaniyan F
    type
    Author
  3. name
    Jabbour E
    type
    Author
  4. name
    Montalban-Bravo G
    type
    Author
  5. name
    Ohanian M
    type
    Author
  6. name
    Chien K
    type
    Author
  7. name
    Kadia T
    type
    Author
  8. name
    Takahashi K
    type
    Author
  9. name
    Masarova L
    type
    Author
  10. name
    Short N
    type
    Author
  11. name
    Alvarado Y
    type
    Author
  12. name
    Yilmaz M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bazinet A
    type
    Author
  2. name
    Darbaniyan F
    type
    Author
  3. name
    Jabbour E
    type
    Author
  4. name
    Montalban-Bravo G
    type
    Author
  5. name
    Ohanian M
    type
    Author
  6. name
    Chien K
    type
    Author
  7. name
    Kadia T
    type
    Author
  8. name
    Takahashi K
    type
    Author
  9. name
    Masarova L
    type
    Author
  10. name
    Short N
    type
    Author
  11. name
    Alvarado Y
    type
    Author
  12. name
    Yilmaz M
    type
    Author
bibliography ids
  1. nci-bib-09b16aea7cb7b7b4d90daf5b
book metadata
content sha256
c34ad711748215d14b79b71b3fba1ae06fbc98f499a7e8a3b40f4085d6008506
document type
citation
dois
  1. 10.1016/S2352-3026(22)00216-2
electronic publication date
display
2022 Sep 2
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:36063832
immutable id
pubmed:36063832@c34ad711748215d14b79b71b3fba1ae06fbc98f499a7e8a3b40f4085d6008506
journal
abbreviation
Lancet Haematol
issn electronic
2352-3026
issn print
Source null
issue
10
name
The Lancet. Haematology
nlm unique id
101643584
pages
e756-e765
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Haematol. 2022 Oct;9(10):e714-e716. doi: 10.1016/S2352-3026(22)00252-6.
    note
    Source null
    related pmid
    36063831
    relationship
    Comment in
outcomes validated
false
pmid
36063832
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
b57086ebe61a55821139dd0705ac782418d26e0f10af46ccc5ef6e10728cf6a0
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Oct
precision
month
year
2022
publication types
  1. Clinical Trial, Phase I
  2. Clinical Trial, Phase II
  3. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/36063832/
title
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.

Preserved source evidence · Not medical advice